Follow
Mariette Labots
Mariette Labots
Medical oncologist, VU University Medical Center, Amsterdam
Verified email at vumc.nl
Title
Cited by
Cited by
Year
Pan-cancer whole-genome analyses of metastatic solid tumours
P Priestley, J Baber, MP Lolkema, N Steeghs, E de Bruijn, C Shale, ...
Nature 575 (7781), 210-216, 2019
9112019
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance
KJ Gotink, HJ Broxterman, M Labots, RR De Haas, H Dekker, ...
Clinical Cancer Research 17 (23), 7337-7346, 2011
3702011
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
L Angus, M Smid, SM Wilting, J van Riet, A Van Hoeck, L Nguyen, ...
Nature genetics 51 (10), 1450-1458, 2019
2962019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
DL van der Velden, LR Hoes, H Van Der Wijngaart, ...
Nature 574 (7776), 127-131, 2019
2302019
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
R Beekhof, C van Alphen, AA Henneman, JC Knol, TV Pham, F Rolfs, ...
Molecular systems biology 15 (4), e8250, 2019
932019
Genomic landscape of metastatic colorectal cancer
JC Haan, M Labots, C Rausch, M Koopman, J Tol, LJM Mekenkamp, ...
Nature communications 5 (1), 5457, 2014
752014
Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study
D de Wit, NP van Erp, J den Hartigh, R Wolterbeek, ...
Therapeutic drug monitoring 37 (3), 331-338, 2015
642015
Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics
JC van der Mijn, M Labots, SR Piersma, TV Pham, JC Knol, ...
Journal of proteomics 127, 259-263, 2015
602015
Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features
PAJ Mendelaar, M Smid, J van Riet, L Angus, M Labots, N Steeghs, ...
Nature communications 12 (1), 574, 2021
592021
Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines
SR Piersma, JC Knol, I de Reus, M Labots, BK Sampadi, TV Pham, ...
Journal of proteomics 127, 247-258, 2015
582015
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells
E Giovannetti, M Labots, H Dekker, E Galvani, JSW Lind, R Sciarrillo, ...
Current pharmaceutical design 19 (5), 927-939, 2013
452013
Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods
SR Piersma, M Labots, HMW Verheul, CR Jiménez
Analytical and bioanalytical chemistry 397, 3163-3171, 2010
432010
Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment
LR Hoes, JM van Berge Henegouwen, H van der Wijngaart, LJ Zeverijn, ...
Clinical Cancer Research 28 (7), 1402-1411, 2022
402022
Sex-and site-specific differences in colorectal cancer risk among people with type 2 diabetes
JA Overbeek, JG Kuiper, AAWA van der Heijden, M Labots, U Haug, ...
International journal of colorectal disease 34, 269-276, 2019
392019
Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection
M Labots, JC van der Mijn, R Beekhof, SR Piersma, RR de Goeij-de Haas, ...
Journal of proteomics 162, 99-107, 2017
312017
Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
M Labots, KJ Gotink, H Dekker, K Azijli, JC Van Der Mijn, CM Huijts, ...
Experimental & Molecular Medicine 48 (12), e279-e279, 2016
282016
Patients with biallelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types
H Van Der Wijngaart, LR Hoes, JM van Berge Henegouwen, ...
Clinical Cancer Research 27 (22), 6106-6114, 2021
252021
Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer
NAM Guman, RJ van Geffen, FI Mulder, TF van Haaps, V Hovsepjan, ...
Journal of Thrombosis and Haemostasis 19 (12), 2974-2983, 2021
222021
Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies
M Labots, LM Schütte, JC van der Mijn, TV Pham, CR Jiménez, ...
The oncologist 19 (10), 1028-1039, 2014
212014
Tumor drug concentration and phosphoproteomic profiles after two weeks of treatment with sunitinib in patients with newly diagnosed glioblastoma
ME Van Linde, M Labots, CG Brahm, KE Hovinga, PC De Witt Hamer, ...
Clinical Cancer Research 28 (8), 1595-1602, 2022
192022
The system can't perform the operation now. Try again later.
Articles 1–20